Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of inequality in maternal and child health outcomes and mortality from 2000 to 2013 in China.

International journal for equity in health·2017
Same author

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Scientific reports·2017
Same author

A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.

Investigative ophthalmology & visual science·2017
Same author

Prenatal exposure to β2-adrenoreceptor agonists and the risk of autism spectrum disorders in offspring.

Pharmacoepidemiology and drug safety·2017
Same author

Chemical constituents from the whole plants of Pilea cavaleriei Levl subsp. cavaleriei.

Fitoterapia·2017
Same author

Semipermeable Functional DNA-Encapsulated Nanocapsules as Protective Bioreactors for Biosensing in Living Cells.

Analytical chemistry·2017

Related Experiment Video

Updated: Aug 23, 2025

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.4K

Clinical translational barriers against nanoparticle-based imaging agents.

Rongrong Jin1, Xiaomin Fu1, Yiyao Pu1

  • 1National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.

Advanced Drug Delivery Reviews
|October 29, 2022
PubMed
Summary

Clinical translation of nanoparticle-based imaging agents (NIAs) faces barriers like complexity and safety. This review analyzes NIA design parameters and suggests strategies to improve clinical success for these advanced diagnostic tools.

Keywords:
Clinical translation barriersComplexityNanoparticle-based imaging agentsNanotoxicityTargeting

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K
Viral Nanoparticles for In vivo Tumor Imaging
14:04

Viral Nanoparticles for In vivo Tumor Imaging

Published on: November 16, 2012

17.3K

Related Experiment Videos

Last Updated: Aug 23, 2025

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.4K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K
Viral Nanoparticles for In vivo Tumor Imaging
14:04

Viral Nanoparticles for In vivo Tumor Imaging

Published on: November 16, 2012

17.3K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Radiology

Background:

  • Nanoparticle-based imaging agents (NIAs) show promise in preclinical research.
  • Clinical translation of NIAs remains limited, hindering their application in patient care.

Purpose of the Study:

  • To investigate barriers hindering the clinical translation of NIAs.
  • To analyze key NIA design parameters and suggest strategies for overcoming translational challenges.

Main Methods:

  • Review of clinical trials involving NIAs.
  • Analysis of NIA design parameters: size, composition, surface characteristics, dosage, administration route, toxicity, biodistribution, and clearance.
  • Examination of regulatory guidelines and manufacturing considerations.

Main Results:

  • Complexity of multifunctional NIAs, inadequate biosafety studies, and heterogeneous uptake/poor targeting efficiency are key barriers.
  • NIA characteristics significantly influence in vivo behavior and clinical efficacy.
  • Regulatory and manufacturing aspects are critical for successful translation.

Conclusions:

  • Addressing NIA complexity, enhancing biosafety assessments, and improving targeting strategies are crucial for clinical success.
  • Optimizing NIA design parameters and adhering to regulatory and manufacturing standards are essential for advancing NIAs from bench to bedside.